153 General discussion and future perspectives 10 Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, Ramamoorthi N, John CR, Watson DS, Kummerfeld SK, Hands R, Riahi S, Rocher-Ros V, Rivellese F, Humby F, Kelly S, Bombardieri M, Ng N, DiCicco M, et al. 2019; Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. Cell Rep. 28(9):2455-2470.e5. 11 Nerviani A, Di Cicco M, Mahto A, Lliso-Ribera G, Rivellese F, Thorborn G, Hands R, Bellan M, Mauro D, Boutet M-A, Giorli G, Lewis M, Kelly S, Bombardieri M, Humby F, Pitzalis C. 2020; A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients. Front Immunol. 11. 12 van der Helm-van Mil AHM, Detert J, Cessie S le, Filer A, Bastian H, Burmester G, Huizinga T, Raza K. 2008; Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum. 58 8. 13 van Aken J, Heimans L, Gillet-van Dongen H, Visser K, Ronday HK, Speyer I, Peeters AJ, Huizinga TW, Allaart CF. 2014; Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Ann Rheum Dis. 73(2):396–400. 14 van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, Speyer I, Westedt ML, Peeters AJ, Allaart CF, Toes RE, Breedveld FC, Huizinga TW. 2007; Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56(5):1424–32. 15 Burgers L, Allaart C, Huizinga T, Mil AHM van der H. 2017; Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example. Arthritis Rheumatol. 69. 16 Niemantsverdriet E, Dakkak YJ, Burgers LE, Bonte-Mineur F, Steup-Beekman GM, van der Kooij SM, Boom HD, Allaart CF, de Jong PHP, van der Helm-van Mil AHM. 2020; TREAT Early Arthralgia to Reverse or Limit Impending Exacerbation to Rheumatoid arthritis (TREAT EARLIER): a randomized, double-blind, placebo-controlled clinical trial protocol. Trials. 21(1):862. 17 Krijbolder DI, Verstappen M, van Dijk BT, Dakkak YJ, Burgers LE, Boer AC, Park YJ, de Witt-Luth ME, Visser K, Kok MR, Molenaar ETH, de Jong PHP, Bohringer S, Huizinga TWJ, Allaart CF, Niemantsverdriet E, van der Helm-van Mil AHM. 2022; Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet. 400(10348):283–94. 18 Krijbolder D, Verstappen M, Dijk B van, Dakkak Y, Burgers L, Boer A, Park YJ, Witt M De, Visser K, Kok MR, Molenaar E, Jong P de, Böhringer S, Huizinga T, Allaart C, Niemantsverdriet E, Mil A van der H. 2022; OP0070 Intervention with methotrexate in arthralgia at risk for rheumatoid arthritis to reduce the development of peristent arthritis and its disease burden (TREAT EARLIER): a double-blind, randomised, placebo-controlled trial. Ann Rheum Dis. 81(Suppl 1):48 LP – 49. 19 Emery P, Durez P, Dougados M, Legerton CW, Becker J, Vratsanos G, Genant H, Peterfy C, Mitra P, Overfield S, Qi K, Westhovens R. 2010; Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 69:510–6. 7
RkJQdWJsaXNoZXIy MTk4NDMw